Literature DB >> 1936009

Prehospital thrombolysis in acute myocardial infarction: the Belgian eminase prehospital study (BEPS). BEPS Collaborative Group.

.   

Abstract

Interest in early thrombolysis has prompted a study on the feasibility and time course of prehospital thrombolysis in patients with acute myocardial infarction (AMI) in six centres in Belgium. Patients with clinically suspected AMI and with typical ECG changes presenting within 4 h after onset of pain were treated with 30 units of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC, eminase) intravenously by a mobile intensive care unit (MICU). Sixty-two patients were included in the study and an AMI was confirmed in 60. The mean time (+/- 1 SD) from onset of pain to injection of APSAC was 95 +/- 47 min and the mean estimated time gain, calculated as the time difference between the arrival of the MICU at home and the arrival of the MICU at the emergency department, was 50 +/- 17 min. In the prehospital period four patients developed ventricular fibrillation and one cardiogenic shock. During hospital stay severe complications were observed in four patients. Two events were fatal, one diffuse haemorrhage and one septal rupture; two events were non fatal, one feasible and that an estimated time gain of 50 min can be obtained. Potential risks and benefits remain to be demonstrated in a large controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936009

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

Review 1.  Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction.

Authors:  Michael McCaul; Andrit Lourens; Tamara Kredo
Journal:  Cochrane Database Syst Rev       Date:  2014-09-10

2.  Prehospital thrombolysis--calculated health benefit for catchment population of one hospital.

Authors:  Mark Kroese; David Kanka; Peter Weissberg; Barbara Arch; John Scott
Journal:  J R Soc Med       Date:  2004-05       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.